Differential responsiveness of proliferation and cytokeratin release to stripped serum and oestrogen in the human breast cancer cell line, MCF-7

European Journal of Cancer

Volumn 32, Issue 5, 1996, Pages 849-856

  Tedone, T ^a   Correale, M ^a   Paradiso, A ^a   Reshkin, S J ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Breast cancer; CYFRA 21.1; Cytokeratins; Growth factors; Hormone; MCF 7; Oestrogen; Proliferation; TPA; TPS

Indexed keywords

CORDYCEPIN; CYTOKERATIN; ESTRADIOL;

ARTICLE; BREAST CANCER; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SERUM;

BREAST NEOPLASMS; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; FEMALE; GROWTH SUBSTANCES; HUMANS; KERATINS; KINETICS; TISSUE POLYPEPTIDE ANTIGEN; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0029940331     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00660-5     Document Type: Article

References (26)

1. Lippman ME, Dickson RB, Kasiol A, et al. Autocrine and paracrine growth regulation of human breast cancer. J Steroid Biochem 1986, 24, 147-154.
2. Moll R. Cytokeratins in the histological diagnosis of malignant tumors. Int J Biol Markers 1994, 9, 63-69.
3. Sundstrom BE, Stigbrand TI. Cytokeratins and tissue polypeptide antigen. Int J Biol Markers 1994, 9, 102-108.
4. Bonfrer JMG, Groeneveld EM, Korse CM van Dalen A, Oomen LCJM, Ivanyi D. Monoclonal antibody M3 used in tissue polypeptide-specific antigen assay for the quantification of tissue polypeptide antigen recognizes keratin 18. Tumor Biol 1994, 4, 210-222.
5. Björklund B, Björklund V. Antigenicity of pooled human malignant and normal tissues by cyto-immunological technique: presence of an insoluble heat-labile tumor antigen. Int Arch Allergy 1957, 10, 153-184.
6. Gion M, Mione R, Becciolini A, et al. Relationship between cytosol TPS, TPA and cell proliferation. Int J Biol Markers 1994, 9, 109-114.
7. Björklund B. Tumor markers TPA, TPA-S and cytokeratins. Tumordiagn Ther 1992, 13, 78-80.
8. Björklund B, Björklund V. Specificity and basis of the tissue polypeptide antigen. Cancer Detect Prev 1983, 6, 41-50.
9. Gion M, Mione R, Dittadi R, Fasan S, Pallini A, Bruscagnin G. Carcinoembrionic antigen, ferritin and tissue polypeptide antigen in serum and tissue. Cancer 1986, 57, 917-922.
10. Gion M, Mione R, Gatti C, et al. Is tissue polypeptide antigen still a useful tumor marker in breast carcinoma? Comparison with Ca 15.3 and MCA. Tumori 1990, 76, 360-364.
11. Gion M, Mione R, Pappagallo GL, et al. Tissue polypeptide antigen in breast cancer cytosol: a new effective prognostic indicator. Eur J Cancer 1993, 29A, 66-69.
12. Lopez-Gonzalez JD, del Moral R, Olea N, Ruiz de Almodovar JM, Pedraza V. Cinetica de proliferacion y de liberacion de antigeno polipeptidico tisular en celulas MCF-7. Influencia hormonal. Revista Espanola de Fisiologia 1989, 45, 227-234.
13. Ruiz de Almodovar JM, Lopez-Gonzalez JD, del Moral R, et al. Liberacion de antigeno polipeptidico tisular y proliferacion de celulas MCF-7 tras sincronizacion con hidroxitamoxifeno y rescate con estradiol. Revista Espanola de Fisiologia 1990, 46, 205-210.
14. Madersbacher S, Schollhammer A, Kramer G, Steiner G, Marberger M. TPS in prostate cancer. Akt Urol 1993, 24, 36-39.
15. Soule HD, Vasquez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion from a breast carcinoma. J Natl Cancer Inst 1973, 51, 1409-1413.
16. Johnson MD, Westley BR, May FEB. Oestrogenic activity of tamoxifen and its metabolites on gene regulation and cell proliferation in MCF-7 breast cancer cells. Br J Cancer 1989, 59, 727-738.
17. Nakazato H, Edmonds M, Kopp DW. Differential metabolism of large and small poly(A) sequences in the heterogeneous nuclear RNA of HeLa Cells. Proc Natl Acad Sci USA 1994, 71, 200-204.
18. Etievant C, Kruczynski A, Pauwels O, Kiss R. The combination of the tetrazolium derivate reduction (MTT) and digital image analysis to monitor in vitro the cytotoxicity of anti-neoplastic drugs. Anticancer Res 1991, 11, 305-312.
19. Alley MC, Sandiero DA, Monks A, et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988, 48, 589-601.
20. Stewart AJ, Westly BR, May FEB. Modulation of the proliferative response of breast cancer cells to growth factors by oestrogen. Br J Cancer 66, 640-648.
21. Pagliacci MC, Tognellini R, Grignani F, Nicoletti I. Inhibition of human breast cancer cell (MCF-7) growth in vitro by the somatostatin analog SMS 201-995: effects on cell cycle parameters and apoptotic cell death. Endocrinology 1991, 129, 2555-2562.
22. Thompson EW, Brunner N, Torri J, et al. The invasive and metastatic properties of hormone-independent but hormone-responsive variants of MCF7 human breast cancer cells. Clin Esp Metastasis 1993, 11, 15-26.
23. King RJB. Estrogen and progestin effects human breast carcinogenesis. Breast Cancer Res Treat 1993, 27, 3-15.
24. Relia C, Coviello M, Quaranta M, Paradiso A. Tissue-type plasminogen activator as marker of functional steroid receptors in human breast cancer. Thrombosis Res 1993, 69, 209-220.
25. Nunez AM, Berry M, Imles JL, Chambou P. The 5′ flanking region of pS2 contains a complex enhancer region responsive to estrogens, epidermal growth factor, a factor promoter (TPA), the c-Ha-ras oncoprotein and c-jun protein. EMBO J 1989, 8, 823-829.
26. Rochefort H, Capony F, Garcia M, Cavaille SV, Freiss G, Chambon M. Estrogen-induced lysosomal proteases secreted by breast cancer cells: a role in carcinogenesis? J Cell Biochem 1987, 35, 17-29.